Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market
August 30, 2016 at 13:23 PM EDT
Canaccord Genuity said Gemphire Therapeutics Inc (NASDAQ: GEMP)'s oral cholesterol drug Gemcabene has a peak U.S. market potential of ...